Tenders Are Invited For Pharmaceutical Products – Amgros 2026 1.1188.A

Pharmaceutical Products – Amgros 2026 1.1188.A. The Tender Number (Sub -Contract) Includes The Following Drugs: Atc Code: B02bd04 · Generic Name: Nonacog Alfa · Dispensing Form: Powder.Sol.Inj.Opl.Pr · Strength: 250 - 500 Ie · Unit Value: 350 Ie · Quantity In Devices: 99 ·· ·· Atc Code: B02bd04 · General Name: Nonacog Alfa · Dispensing Form: Powder.Sol.Inj.Opl.Spr · Strength: 1000 Ie · Unit Value: 350 Ie · Quantity In Units: 140 ··· Atc Code: B02bd04 · Generic Name: Nonacog Alfa · Dispensing Form: Powder · Quantity In Devices: 771 ··· Atc Code: B02bd04 · Generic Name: Nonacog Alfa · Dispensing Form: Powder.Sol.Inj.Opl. A Supplier Can Thus Choose To Offer One, More Or All Tendering Numbers, And Allocation Is Done Separately For Each Tender Number. A Supplier Can Thus Be Assigned One, More Or All Sub -Contracts. Reference Is Made To The Tender Conditions, Including On Submitting Tenders Under The Individual Tendering Numbers. Under The Term Quantity In Units Above, An Estimated Consumption Of The Medicines Is Indicated Under The Tender Number, But The Real Consumption May Differ Significantly From There. This Is What The Suppliers Must Expect. The Reason For This Is That There Are Medicines For Patient Treatment In Public Hospitals Where The Patients Needs Must Be Met. The Medicines Offered Are Also Covered By One Or More Recommendations And/Or Treatment Guides From The Medicines Council, And The Consumption Of The Various Medicines Can Be Significantly Affected By It. For More Detailed Description, Refer To The Tendering Terms And The Framework Agreement. The One Below Under Par. 5.1.5 Maximum Value Of The Sub -Contract Is Calculated As A Proportion Of 100 % Of The Estimated Total Value Of All Sub -Contracts Referred To In Par. 2.1.3. It Is Due To The Fact That All The Medicines Offered Are Covered By One Or More Recommendations And/Or Treatment Instructions From The Medicines Council, Which Assess Which Of The Medicines Offered For Treatment For Various Patient Populations, Possibly So That Certain Medications Are Considered Equal Possible First Choice Are Recommended For Use In Priority Order Or Similar. The Medicines Councils Assessment May Therefore Have A Significant Impact On Which Of The Drugs Offered In Different Therapy Areas And Patient Populations, And The Consumption Of The Individual Medicines May Also Depend On Current Agreement Prices. This Means That The Supply Is Not Possible To Estimate Which Drugs Will Primarily Be Used During The Term Of The Framework Agreement, And It Is Possible That The Use Of The Drugs Can Be Changed Significantly During The Maturity Of The Framework Agreements, Including In Particular When Approving New Indications For The Individual Medicines, Changed Treatment Of One Or More Patient Populations And The Like. Fixing The Maximum Value Of The Simple